Trial Profile
A phase I study of Docetaxel-Gefitinib for patients with gefitinib refractory non-small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Sep 2015
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 01 Apr 2013 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 31 Aug 2012 Planned End Date changed to 1 Aug 2014 as reported by University Hospital Medical Information Network - Japan.
- 03 Sep 2008 New trial record.